Clinical Efficacy Data

Longevity: Demonstrates visible volume retention for up to 18 months in mid-face applications (Source: ClinicalTrials.gov NCT02434657).

Integration: 95% patient satisfaction rate regarding natural facial movement preservation at 12-week post-treatment follow-up.

Global Usage: Documented in over 10 million aesthetic procedures globally.

CPM® Technology Mechanism

Cohesive Polydensified Matrix (CPM) utilizes a dynamic, double cross-linking process. This yields a monophasic gel containing dual zones:

Low-Density Zones: Ensure seamless diffusion into dermal tissue spaces, preventing lump formation and the Tyndall effect in superficial injections.

High-Density Zones: Provide necessary rheological properties (G-prime/elasticity) for optimal tissue lifting and structural support.

1. Site Preparation: Disinfect injection site with chlorhexidine or 70% isopropyl alcohol.

2. Injection Technique: Employ linear retro-tracing, serial puncture, or fanning techniques based on indication depth.

3. Dosage Limit: Maximum 2.0mL per individual treatment zone per session to mitigate edema risk.

⚠ Contraindications & Safety Data

Adverse Events (AEs): Clinical trials report localized erythema, edema, and ecchymosis (bruising) in <5% of patients, typically resolving within 3-7 days.

Absolute Contraindications: Known history of anaphylaxis, multiple severe allergies, active facial infections (e.g., Herpes simplex), bleeding disorders, pregnancy, or lactation.